CR8233A - Anticuerpos humanos modificados anti-igf-1r - Google Patents
Anticuerpos humanos modificados anti-igf-1rInfo
- Publication number
- CR8233A CR8233A CR8233A CR8233A CR8233A CR 8233 A CR8233 A CR 8233A CR 8233 A CR8233 A CR 8233A CR 8233 A CR8233 A CR 8233A CR 8233 A CR8233 A CR 8233A
- Authority
- CR
- Costa Rica
- Prior art keywords
- igf
- human antibodies
- replaced
- modified human
- germ line
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
Abstract
La presente invencion se refiere a anticuerpos humanos, por ejemplo aquellos dirigidos al receptor del IGF-1 humano(IGF-1R) para el tratamiento del cancer y tienen uno o mas restos mutados seleccionados reemplazados por restos de la linea germinal. Un resto reemplazados por restos de la linea germinal. Un resto reemplazado puede ser una mutacion somatica en una region marco conservada.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49520003P | 2003-08-13 | 2003-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR8233A true CR8233A (es) | 2007-01-18 |
Family
ID=34193291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR8233A CR8233A (es) | 2003-08-13 | 2006-02-13 | Anticuerpos humanos modificados anti-igf-1r |
Country Status (37)
Country | Link |
---|---|
US (2) | US7371378B2 (es) |
EP (1) | EP1656391B1 (es) |
JP (1) | JP4638870B2 (es) |
KR (1) | KR100825156B1 (es) |
CN (1) | CN1835975B (es) |
AP (1) | AP2006003510A0 (es) |
AR (1) | AR045247A1 (es) |
AT (1) | ATE484525T1 (es) |
AU (1) | AU2004265152A1 (es) |
BR (1) | BRPI0413466A (es) |
CA (1) | CA2535071A1 (es) |
CL (1) | CL2004002035A1 (es) |
CR (1) | CR8233A (es) |
DE (1) | DE602004029581D1 (es) |
DK (1) | DK1656391T3 (es) |
EA (1) | EA200600234A1 (es) |
EC (1) | ECSP066359A (es) |
ES (1) | ES2351395T3 (es) |
GT (1) | GT200400158A (es) |
IL (1) | IL173273A (es) |
IS (1) | IS8266A (es) |
MA (1) | MA27988A1 (es) |
MX (1) | MXPA06001634A (es) |
NL (1) | NL1026829C2 (es) |
NO (1) | NO20060542L (es) |
OA (1) | OA13234A (es) |
PA (1) | PA8608801A1 (es) |
PE (1) | PE20050339A1 (es) |
PL (1) | PL1656391T3 (es) |
PT (1) | PT1656391E (es) |
RS (1) | RS20060099A (es) |
TN (1) | TNSN06050A1 (es) |
TW (1) | TWI294915B (es) |
UA (1) | UA85058C2 (es) |
UY (1) | UY28464A1 (es) |
WO (1) | WO2005016967A2 (es) |
ZA (1) | ZA200601231B (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME00502B (me) | 2001-01-05 | 2011-10-10 | Amgen Fremont Inc | Antitjela za insulinu sličan receptor faktora i rasta |
NZ554740A (en) | 2002-05-24 | 2009-01-31 | Schering Corp | Neutralizing human anti-IGFR antibody |
EP1622942B1 (en) * | 2003-05-01 | 2014-11-19 | ImClone LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
EP1656391B1 (en) * | 2003-08-13 | 2010-10-13 | Pfizer Products Inc. | Modified human igf-1r antibodies |
CA2545755A1 (en) | 2003-11-12 | 2005-05-26 | Schering Corporation | Plasmid system for multigene expression |
AR046639A1 (es) | 2003-11-21 | 2005-12-14 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti- igfr1 |
KR20070036130A (ko) | 2004-07-16 | 2007-04-02 | 화이자 프로덕츠 인코포레이티드 | 항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료 |
FR2873699B1 (fr) * | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | Nouveaux anticorps anti igf ir rt leurs utilisations |
ES2356830T3 (es) | 2004-12-03 | 2011-04-13 | Schering Corporation | Biomarcadores para preselección de pacientes para terapia de anti-igf-1r. |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
GB0500417D0 (en) * | 2005-01-10 | 2005-02-16 | Cambridge Antibody Tech | Method of mutagenesis |
NZ561648A (en) * | 2005-04-15 | 2009-11-27 | Schering Corp | Methods and composition of IGF1R inhibitors for treating or preventing cancer |
KR20080019249A (ko) * | 2005-06-15 | 2008-03-03 | 쉐링 코포레이션 | 안정한 항체 제형 |
SI2100618T1 (sl) | 2005-06-17 | 2014-03-31 | Imclone Llc | Antagonisti receptorja za zdravljenje metastaznega kostnega raka |
FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
CN101484587B (zh) * | 2006-02-03 | 2014-02-12 | 英克隆有限责任公司 | Igf-ir拮抗剂作为辅药用于***癌的治疗 |
CA2647111A1 (en) * | 2006-03-28 | 2007-10-04 | F. Hoffmann-La Roche Ag | Anti-igf-1r human monoclonal antibody formulation |
US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
WO2007141626A1 (en) | 2006-06-02 | 2007-12-13 | Pfizer Products Inc. | Circulating tumor cell assay |
TW200833711A (en) * | 2006-12-22 | 2008-08-16 | Genentech Inc | Antibodies to insulin-like growth factor receptor |
GB0702888D0 (en) * | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
AU2012203443B2 (en) * | 2007-03-02 | 2014-03-06 | Amgen Inc. | Methods and compositions for treating tumor diseases |
JP2010520204A (ja) * | 2007-03-02 | 2010-06-10 | アムジェン インコーポレイテッド | 腫瘍疾患を治療するための方法および組成物 |
BRPI0809112A2 (pt) * | 2007-03-22 | 2014-08-26 | Imclone Llc | Formulações estáveis de anticorpos |
EP2145021A2 (en) | 2007-05-17 | 2010-01-20 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
ES2388017T3 (es) | 2007-12-21 | 2012-10-05 | Roche Glycart Ag | Ensayo de estabilidad de anticuerpos |
WO2009142810A2 (en) * | 2008-03-25 | 2009-11-26 | Schering Corporation | Methods for treating or preventing colorectal cancer |
MX2010012064A (es) * | 2008-05-05 | 2010-12-06 | Schering Corp | Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer. |
EP2356154A4 (en) * | 2008-11-06 | 2012-12-19 | Alexion Pharma Inc | DEVELOPMENT OF REDUCED IMMUNOGENICITY ANTIBODIES AND METHODS OF MANUFACTURING THEREOF |
JP2012518657A (ja) | 2009-02-25 | 2012-08-16 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 併用抗癌治療 |
EP2236139A1 (en) | 2009-03-31 | 2010-10-06 | F. Hoffmann-La Roche AG | Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor |
US20100316639A1 (en) | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
TWI513465B (zh) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以dll4拮抗劑與化學治療劑治療癌症之方法 |
AU2010311567B2 (en) | 2009-10-26 | 2015-03-26 | Chugai Seiyaku Kabushiki Kaisha | Method for the production of a glycosylated immunoglobulin |
EP2494070A2 (en) | 2009-10-30 | 2012-09-05 | Bristol-Myers Squibb Company | Methods for treating cancer in patients having igf-1r inhibitor resistance |
AU2014262201B2 (en) * | 2009-12-23 | 2016-09-15 | Novartis Ag | Method for decreasing immunogenicity |
EP2516461A1 (en) | 2009-12-23 | 2012-10-31 | ESBATech, an Alcon Biomedical Research Unit LLC | Method for decreasing immunogenicity |
WO2011101328A2 (en) | 2010-02-18 | 2011-08-25 | Roche Glycart Ag | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor |
WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
CA2804185C (en) | 2010-07-12 | 2017-03-21 | Covx Technologies Ireland Limited | Multifunctional antibody conjugates |
JP2014510265A (ja) | 2011-02-02 | 2014-04-24 | アムジェン インコーポレイテッド | Igf−1rの阻害に関する方法および組成物 |
ES2724801T3 (es) | 2011-04-19 | 2019-09-16 | Pfizer | Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer |
EP2766497A1 (en) | 2011-10-13 | 2014-08-20 | Bristol-Myers Squibb Company | Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors |
ES2700398T3 (es) | 2012-01-09 | 2019-02-15 | Pfizer Healthcare Ireland | Anticuerpos mutantes y conjugación de los mismos |
EP2631653A1 (en) | 2012-02-24 | 2013-08-28 | Charité - Universitätsmedizin Berlin | Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
BR112015010240A2 (pt) * | 2012-11-06 | 2017-08-22 | Medimmune Ltd | Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas |
AU2014261630B2 (en) | 2013-04-29 | 2019-05-09 | F. Hoffmann-La Roche Ag | Human FcRn-binding modified antibodies and methods of use |
CN103319598B (zh) * | 2013-05-13 | 2014-10-22 | 杭州德同生物技术有限公司 | 抗***-1受体抗体及其编码基因和应用 |
MX2016008782A (es) | 2014-01-15 | 2016-09-08 | Hoffmann La Roche | Variantes de region fc con union mejorada de la proteina a. |
KR20200100589A (ko) * | 2017-07-27 | 2020-08-26 | 아이테오스 테라퓨틱스 에스에이 | 항-tigit 항체 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9203459D0 (en) * | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
CA2761116A1 (en) | 1995-04-27 | 1996-10-31 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
IL118626A0 (en) | 1996-06-11 | 1996-10-16 | Xtl Biopharmaceuticals Limited | Anti HBV antibody |
DE69712496T2 (de) | 1996-07-18 | 2002-08-29 | Pfizer | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren |
KR20000068248A (ko) | 1996-08-23 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 아릴설포닐아미노 하이드록삼산 유도체 |
JP2002515511A (ja) | 1998-05-15 | 2002-05-28 | イムクローン システムズ インコーポレイティド | 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療 |
EE05627B1 (et) * | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
JP4841038B2 (ja) | 1999-03-25 | 2011-12-21 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ヒトil−12に結合するヒト抗体およびその産生法 |
ES1042735Y (es) | 1999-04-07 | 2000-02-16 | Martinez Fernando Martinez | Vehiculo tripersonal de accionamiento a pedales. |
US20030165502A1 (en) | 2000-06-13 | 2003-09-04 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
DE10033869C2 (de) | 2000-07-12 | 2003-07-31 | Karlsruhe Forschzent | HTS-Kryomagnet und Aufmagnetisierungsverfahren |
ME00502B (me) * | 2001-01-05 | 2011-10-10 | Amgen Fremont Inc | Antitjela za insulinu sličan receptor faktora i rasta |
ES2398099T3 (es) | 2001-02-19 | 2013-03-13 | Merck Patent Gmbh | Anticuerpos anti-EGFR modificados con inmunogenicidad reducida |
DE60312639T2 (de) | 2002-01-18 | 2007-11-29 | Pierre Fabre Médicament | Antikörper gegen igf-ir und ihre verwendungen |
CA2483848C (en) | 2002-04-30 | 2012-08-21 | Kyowa Hakko Kogyo Co., Ltd. | Antibody against human insulin-like growth factor |
NZ554740A (en) * | 2002-05-24 | 2009-01-31 | Schering Corp | Neutralizing human anti-IGFR antibody |
GB0212303D0 (en) | 2002-05-28 | 2002-07-10 | Isis Innovation | Molecular targetting of IGF-1 receptor |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
CN101164616A (zh) | 2003-02-13 | 2008-04-23 | 辉瑞产品公司 | 抗-***i受体抗体的用途 |
CA2518980A1 (en) | 2003-03-14 | 2004-09-30 | Pharmacia Corporation | Antibodies to igf-i receptor for the treatment of cancers |
ES2383014T3 (es) | 2003-04-02 | 2012-06-15 | F. Hoffmann-La Roche Ag | Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos |
EP1656391B1 (en) * | 2003-08-13 | 2010-10-13 | Pfizer Products Inc. | Modified human igf-1r antibodies |
-
2004
- 2004-08-03 EP EP04744197A patent/EP1656391B1/en active Active
- 2004-08-03 AU AU2004265152A patent/AU2004265152A1/en not_active Abandoned
- 2004-08-03 AT AT04744197T patent/ATE484525T1/de active
- 2004-08-03 JP JP2006523070A patent/JP4638870B2/ja not_active Expired - Fee Related
- 2004-08-03 BR BRPI0413466-4A patent/BRPI0413466A/pt not_active IP Right Cessation
- 2004-08-03 OA OA1200600046A patent/OA13234A/en unknown
- 2004-08-03 AP AP2006003510A patent/AP2006003510A0/xx unknown
- 2004-08-03 PL PL04744197T patent/PL1656391T3/pl unknown
- 2004-08-03 DE DE602004029581T patent/DE602004029581D1/de active Active
- 2004-08-03 PT PT04744197T patent/PT1656391E/pt unknown
- 2004-08-03 RS YUP-2006/0099A patent/RS20060099A/sr unknown
- 2004-08-03 UA UAA200601349A patent/UA85058C2/ru unknown
- 2004-08-03 EA EA200600234A patent/EA200600234A1/ru unknown
- 2004-08-03 CN CN2004800230991A patent/CN1835975B/zh not_active Expired - Fee Related
- 2004-08-03 DK DK04744197.7T patent/DK1656391T3/da active
- 2004-08-03 KR KR1020067002957A patent/KR100825156B1/ko not_active IP Right Cessation
- 2004-08-03 ES ES04744197T patent/ES2351395T3/es active Active
- 2004-08-03 MX MXPA06001634A patent/MXPA06001634A/es unknown
- 2004-08-03 WO PCT/IB2004/002555 patent/WO2005016967A2/en active Application Filing
- 2004-08-03 CA CA002535071A patent/CA2535071A1/en not_active Abandoned
- 2004-08-09 PE PE2004000773A patent/PE20050339A1/es not_active Application Discontinuation
- 2004-08-10 CL CL200402035A patent/CL2004002035A1/es unknown
- 2004-08-11 AR ARP040102870A patent/AR045247A1/es active IP Right Grant
- 2004-08-11 UY UY28464A patent/UY28464A1/es not_active Application Discontinuation
- 2004-08-12 TW TW093124269A patent/TWI294915B/zh not_active IP Right Cessation
- 2004-08-12 GT GT200400158A patent/GT200400158A/es unknown
- 2004-08-12 NL NL1026829A patent/NL1026829C2/nl not_active IP Right Cessation
- 2004-08-12 PA PA20048608801A patent/PA8608801A1/es unknown
- 2004-08-12 US US10/917,073 patent/US7371378B2/en not_active Expired - Fee Related
-
2006
- 2006-01-19 IL IL173273A patent/IL173273A/en not_active IP Right Cessation
- 2006-01-26 IS IS8266A patent/IS8266A/is unknown
- 2006-02-02 NO NO20060542A patent/NO20060542L/no not_active Application Discontinuation
- 2006-02-10 ZA ZA200601231A patent/ZA200601231B/en unknown
- 2006-02-10 EC EC2006006359A patent/ECSP066359A/es unknown
- 2006-02-13 MA MA28790A patent/MA27988A1/fr unknown
- 2006-02-13 TN TNP2006000050A patent/TNSN06050A1/fr unknown
- 2006-02-13 CR CR8233A patent/CR8233A/es not_active Application Discontinuation
-
2008
- 2008-03-03 US US12/041,341 patent/US7575746B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR8233A (es) | Anticuerpos humanos modificados anti-igf-1r | |
CY1118691T1 (el) | Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης | |
BRPI0914678A8 (pt) | Dispositivo dispensador para vaso sanitário e processo para distribuir uma composição de tratamento a um dispositivo sanitário | |
UA96424C2 (ru) | Циклопропил амины как модуляторы н3 рецепторов гистамина | |
PE20130324A1 (es) | Proteinas de fusion que comprenden un antigeno prame (dage) | |
SV2006002143A (es) | Uso de un anticuerpo para el tratamiento del cancer resistente al platino | |
CR20130351A (es) | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina (diviisional 9819) | |
UY29357A1 (es) | Agonistas de pyy y sus usos | |
TNSN07150A1 (en) | Semi-soft c-class immunostimulatory oligonucleotides | |
DOP2005000248A (es) | Agentes citotoxicos que comprendentaxanos nuevos. | |
CL2007002331A1 (es) | Composicion oral solida que comprede uno o mas farmacos antirretrovirales y al menos un polimero insoluble en agua, en relacion aproximadamente 1:1 hasta 1:6; proceso de elaboracion; y uso para el tratamiento del vih. | |
NO20060093L (no) | Plate glykoprotein IB alfa-variant fusjonspolypeptider og fremgangsmater for anvendelse derav | |
DE602006002894D1 (de) | Naphthyridinverbindungen | |
PA8654201A1 (es) | Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2 | |
CR10826A (es) | Composiciones y metodos para suprimir la proliferacion endometrial | |
CO2020006443A2 (es) | Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas | |
CR20110037A (es) | Derivados de ácido fenoxicroman carboxílico 6-sustituido | |
NO20073369L (no) | Modulatorer av muskarinreseptorer | |
CR11529A (es) | Compuestos de cicloalquiloxi y heterocicloalquilopiridina como moduladores del receptor de h3 de histamina | |
ATE509638T1 (de) | Uv-desinfektionsvorrichtung | |
CL2011001034A1 (es) | Compuestos derivados de pirrolidina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como endometriosis, fibroides uterinos, menorragia, entre otras. | |
AR067391A1 (es) | Composiciones para el cuidado del cabello | |
DOP2004000975A (es) | Anticuerpos humanos modificados anti-igf-1g | |
CR20110012A (es) | Compuestos de fenantrenona, composiciones y métodos | |
CY1110846T1 (el) | Διαμορφωτες υποδοχεων της προγεστερονης του τυπου πυριδοοξαζεπινης |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |